Abarelix Evidence Guide
Abarelix has historical FDA approval but is no longer marketed in the United States. Its immediate systemic allergic-reaction risk sharply limited use, and currently available GnRH antagonists have replaced it. It is a historical pharmacology reference, not a current treatment option.
Our Take
Abarelix has historical FDA approval but is no longer marketed in the United States. Its immediate systemic allergic-reaction risk sharply limited use, and currently available GnRH antagonists have replaced it. It is a historical pharmacology reference, not a current treatment option.
- Evidence context
- Historical GnRH antagonist pharmacology reference only - not recommended for new research protocols
- Evidence grade
- Level A
- Confidence
- Moderate
- Reference context
- Reported research reference: Not recommended due to anaphylaxis risk - degarelix is the appropriate alternative
Benefits and Evidence
- Rapid Testosterone Suppression: Level A, includes human evidence - Achieves castrate testosterone in >75% of patients by day 8 and >99% by day 29 without the initial testosterone flare seen with GnRH agonists. Critical for patients with symptomatic disease.
- Prostate Cancer Disease Control: Level A, includes human evidence - Maintains castrate testosterone levels comparable to leuprolide depot. PSA declines are equivalent to standard androgen deprivation therapy.
- Allergic Reaction Risk: Level A, includes human evidence - Immediate-onset systemic allergic reactions observed in approximately 3.7% of patients, including hypotension, syncope, and urticaria. This has significantly limited its clinical adoption.
Side Effects and Warnings
- Immediate-onset allergic reactions (3.7%)
- Hot flashes
- Sleep disturbances
- Breast enlargement
- Pain at injection site
- Constipation
- Peripheral edema
- Fatigue
Research Dosage References
- <strong>Intramuscular</strong> - 100 mg - Day 1, Day 15, Day 29, then every 4 weeks - Must be administered in healthcare setting with 30-minute post-injection observation due to allergic reaction risk. Supplied as powder for reconstitution.
Mechanism of Action
Abarelix achieves immediate gonadotropin suppression through competitive GnRH receptor antagonism: 1. Competitive blockade: Binds the pituitary GnRH receptor with high affinity, preventing endogenous GnRH from triggering LH and FSH release. 2. No flare effect: Unlike agonists, there is no initial surge in testosterone. LH, FSH, and testosterone begin declining immediately. 3. Rapid castration: Castrate testosterone levels (<50 ng/dL) achieved within 1 week in most patients, compared to 2-4 weeks with GnRH agonists. 4. Depot formulation: Intramuscular injection creates a depot at the injection site, providing sustained drug release over approximately 2 weeks per injection.
Legal Status
Plenaxis received FDA approval in 2003 under a restricted program but was discontinued and is no longer marketed in the United States. Abarelix therefore has historical FDA approval, not a currently available FDA-approved product. Its immediate systemic allergic-reaction risk was a major limitation.
Primary Sources
- Abarelix depot versus leuprolide acetate for prostate cancer. Journal of Urology, 2002.
- Immediate-onset reactions to abarelix in prostate cancer patients. Urology, 2003.
Quick Answers
Where is the strongest evidence for Abarelix?
Abarelix has historical FDA approval but is no longer marketed in the United States. Its immediate systemic allergic-reaction risk sharply limited use, and currently available GnRH antagonists have replaced it. It is a historical pharmacology reference, not a current treatment option. Evidence context: Historical GnRH antagonist pharmacology reference only - not recommended for new research protocols.
What are the main side effects of Abarelix?
Abarelix side effects and warning signals include Immediate-onset allergic reactions (3.7%), Hot flashes, Sleep disturbances, Breast enlargement, and Pain at injection site.
What evidence level is Abarelix?
Abarelix is rated Level A; the listed research status is Historical FDA Approval.